The Shift in Workplace Communication

 

One of the biggest challenges we’ve all faced in light of COVID-19, is a rapid transition from active to passive communication, especially in the workplace. When passive communication occurs, such as an email or text message, the recipient reads it, reacts to it, and then chooses to communicate or not by responding or ignoring the message. Because many employees are no longer working together in an office, there are much less opportunities for active communication, as you can’t walk up to someone’s desk if you need to speak to them. Now if you want to speak with someone audibly or visually, you need to schedule and wait for a phone or video meeting to occur.

While this shift to almost entirely passive communication has its challenges, Nasheen Liu, Founding Partner, The IT Media Group, sees potential benefits. “What this crisis has done, is that in some ways, or in a lot of ways, it actually has dismantled this stiff buttoned down corporate facade and it allows us to be more human. And we’ve discovered us, as real people, and with real lives. And you know, and this discovery is quite liberating for us as individuals, as well as businesses, when we communicate to others,” Liu said. She feels this is especially true when we communicate with our business partners, staff, and customers. “It really cuts down to what’s really important, right, so we allow ourselves to all of a sudden to be more direct, more honest, more open. And with the level of transparency, we’ve never experienced before. And there’s also that human layer, that humanity layer, right. So we are now more empathetic, show more compassion in our day to day communication, whether it be with our teams, or customers, or just a corporate communication to businesses,” Liu explained.

Make Sure to Subscribe to The Suite Spot to Stay Up to Date!

Follow us on social media for the latest updates in B2B!

Image

Latest

resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More
Evolving Biomarkers: Charting the Future of Precision Medicine
April 19, 2025

In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity and scope of biomarker use has increased alongside technological advances. A key success story like the BCR-ABL biomarker in chronic myeloid leukemia…

Read More